PHXM PHAXIAM THERAPEUTICS

Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2022

Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2022



                Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2022.

Article 223-16 of general regulation of French Autorité des Marchés Financiers

Lyon – France


Listing markets:

Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) &

Nasdaq Global Select Market in the United-States (Symbol : ERYP)

Website :

DateTotal of shares composing the share capitalTotal of brut (1) voting rights



Total of net (2) voting rights



December 31, 202131 018 55332 518 33932 515 839
January 31, 202231 018 55332 518 33932 515 839
February 28, 202231 018 55332 518 54732 516 047
March 31, 202231 018 55332 518 54732 516 047
April 30, 202231 018 55332 518 54732 516 047
May 31, 202231 018 55332 518 54732 516 047
June 30, 202231 018 55332 520 10732 517 607
July 31, 202231 018 55332 521 12632 518 626

(1)   Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including shares without voting rights.

(2)   Without treasury shares.

Attachment



EN
06/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PHAXIAM THERAPEUTICS

 PRESS RELEASE

PHAXIAM Therapeutics announces high coverage performance of its two an...

PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains PHAXIAM Therapeutics announces high coverage performanceof its two anti-Staphylococcus aureus phages over clinical strains Data from PHAXIAM’s phagogram, first CE-marked Phage Susceptibility Test (PST), showed 98% response rate over 105 clinical S. aureus strains Lyon (France) et Cambridge (MA, US), October 9, 2023 at 10:05pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced a very high spectrum of activity of its anti-S. aureus (PP1493 and PP181...

 PRESS RELEASE

PHAXIAM Therapeutics annonce un niveau de performance élevé de ses deu...

PHAXIAM Therapeutics annonce un niveau de performance élevé de ses deux phages anti-Staphylococcus aureus sur des souches cliniques PHAXIAM Therapeutics annonce un niveau de performance élevé de ses deux phages anti-Staphylococcus aureus sur des souches cliniques Les données obtenues à partir du phagogramme développé par PHAXIAM, le premier test de sensibilité aux phages disposant du marquage CE, ont montré un taux de réponse de 98% sur 105 souches cliniques de S. aureus Lyon (France) et Cambridge (MA, US), le 9 octobre 2023 - 22h05 CEST – PHAXIAM Therapeutics (Nasdaq & Euronext : PHXM), ...

 PRESS RELEASE

PHAXIAM Receives Compliance Notice from Nasdaq

PHAXIAM Receives Compliance Notice from Nasdaq PHAXIAM Receives Compliance Notice from Nasdaq Lyon (France) et Cambridge (MA, US), October 4, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced that it has received confirmation from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2). With closing bid price of PHAXIAM’s American Depositary Shares (“ADSs”) above $1.00 per ADS for the 10 consecutive business days from September 18 through September 29, 2023, PHAXIAM has regained compliance with Listing Rule 5550(a)(2). On October 7, 202...

 PRESS RELEASE

PHAXIAM reçoit un avis de conformité du Nasdaq

PHAXIAM reçoit un avis de conformité du Nasdaq PHAXIAM reçoit un avis de conformité du Nasdaq Lyon (France) et Cambridge (MA, US), le 4 octobre 2023, 22h05 CEST – PHAXIAM Therapeutics (Nasdaq & Euronext : PHXM), annonce aujourd'hui avoir reçu la confirmation du Nasdaq d’être à nouveau en conformité avec la règle de cotation 5550(a)(2). Avec un cours de clôture des American Depositary Shares (« ADS ») de PHAXIAM supérieur à 1,00 $ par ADS pendant les 10 jours ouvrables consécutifs du 18 septembre au 29 septembre 2023, PHAXIAM est de nouveau en conformité avec la règle de cotation 5550(a)(2...

 PRESS RELEASE

PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collab...

PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinary phage therapy Combining expertise in the research of new phages and phage endolysins that could be applied to human healthExclusive phage and endolysin licensing options in human health for PHAXIAM Therapeutics Lyon (France) and Cambridge (MA, US), October 03, 2023 – 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq &...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch